- Created by Daniel Liu, last modified by Tom Adams on Apr 27, 2021
Ruth Ruprecht: Thank you Jeff [Lifson] and good evening everybody. Jeff has given you a slide. Could you cut down to the slides please? A slide showing you the origin of many of those SIVs, but I would like to point out that there is actually one other origin and that is man-made viruses, and they are using macaque, rhesus macaque. Those man-made viruses [00:00:30] are actually not the topic of tonight's session. So, for that reason, I just highlighted for you briefly what they taught us and I conveniently highlighted it in red already.
These man-made SHIVs (simian-human immunodeficiency viruses) with HIV-1 envelopes (env) have been used for passive immunizations and for active immunizations by a number of groups, including our own. They showed the principle of [00:01:00] sterile protection with monoclonal antibodies, including prevention of viremia when you use post-exposure prophylaxis regimens. They showed us that the effector function of IgG1s (immunoglobulin subclass G1) is critical. They showed complete protection of neonates by transplacental or neonatal human IgG1 and monoclonal antibody combination, cross-clade protection. And then a relatively newer set of data [00:01:30] on the proof of principle for immune exclusion by placing monoclonal dimeric IgAs (immunoglobulin subclass A) into the mucosal lumen.
Of course, there is the work that's ongoing right now, generating SHIVs with the transmitted/founder virus HIV genes. Of course, with active immunization, the SHIVs not only have the HIV-1 envelope but also the HIV-1 tat gene. Theoretically, the use [00:02:00] of these SHIVs also allows you to directly analyze correlates of protection and evaluate vaccine candidates with these real HIV-1 genes. I'm done, and I'll—
Jeffrey Lifson: Thank you Ruth. With that, it's—
[00:02:16] [END OF AUDIO]
Ruth M. Ruprecht is a geneticist and oncologist, previously at Harvard Medical School, and currently with Texas Biomedical Research Institute and UT Health San Antonio.
Jump to:
Index
- 4.0.1 Jeffrey Lifson — Session 4, Introduction 1
- antibody, immunoglobulin (Ig)
- env
- HIV vaccine
- macaque, rhesus macaque
- monoclonal antibody
- prevention of HIV/AIDS
- simian immunodeficiency virus (SIV)
- simian-human immunodeficiency virus (SHIV)
- tat
- viremia
Found 8 search result(s) for Ruprecht.
... Chairs: Jeffrey Lifson (National Cancer Institute) and Ruth Ruprecht (Texas Biomedical Research Institute
Mar 18, 2021
... terrific speakers in this evening's session to address each of these points. My cochair, Ruth Ruprecht, wanted to make a couple of comments and then we'll get onto our first presentation ...
Apr 27, 2021
... longer to get into these other fields, but I believe that this will be useful for a lot of things. Ruth Ruprecht: 00:27:00 Mike, what you have described as evolution based ...
Apr 27, 2021
... those people from the first half of the meeting. 00:30:19 Ruth Ruprecht: John, this was a really enjoyable summary of the history. I want to congratulate you on one ...
Apr 27, 2021
... virus that we're all interested in. Thank you very much. applause Ruth Ruprecht (Moderator): 00:27:30 Thank you very much, Mike, for a great ...
Apr 27, 2021
... 00:07:30 evidence, people have shown early on like Ruth Ruprecht and other people that in the nonhuman primates, again, that natural antibodies are very important, but they are difficult ...
Apr 27, 2021
... what's left when you stop viral replication. Alan: Ruth? Ruth Ruprecht: Hi, beautiful work. We looked at the distribution of fulllength proviral DNA in the SIVmac239 ...
Apr 27, 2021
... time. Thank you very much. applause 00:34:30 Ruth Ruprecht (Moderator): Thank you, Beatrice. Questions, Doug. Douglas Richman: So B ...
Nov 11, 2021
- No labels